"SBPGroup's recent out-licensing agreements reflect growing recognition of our innovation capabilities ... "Partnering with SBP Group and CTTQ on pembrolizumab and further molecules accelerates STADA's growth in biosimilars.
“Justin Brownlee will miss the game against Australia due to hamstring strain and peroneal tendinopathy on his right leg and left knee swelling and cartilage defects,” the SBP posted ... ....
The SBP accepted Rs 12,240 billion against 35 quotes at 11.51% rate of return. The total amount offered at 11.51% was Rs 5,979 billion, out of which SBP accepted Rs 5,478.8 billion on a pro-rata basis.